Professional paper
Bevacizumab-associated sudden onset of multiple monomorphic comedones on the scalp successfully treated with 30% salicylic acid peels.
Eftychia Platsidaki
; MD
Evgenia Balamoti
; MD
Anargyros Kouris
; PhD
Alexandra Katsarou
; MD
Nikolaos Mylonakis
; MD
Charitomeni Vavouli
; MD
Georgios Kontochristopoulos
; PhD
Abstract
Bevacizumab is a humanized monoclonal antibody against vascular endothelial factor (VEGF) that targets tumor cell angiogenesis and proliferation. Although it is usually well tolerated, many side-effects have been reported. These include hypertension, bleeding, and thromboembolic events among others. Drug-associated cutaneous adverse effects are less common and include itching, exfoliative dermatitis, and acneiform eruptions. A man with bevacizumab-associated monomorphic skin eruption successfully was treated with 30% salicylic acid peels. To the author’s knowledge, this is the first report of open comedones with no further inflammatory acne lesions that developed in a patient treated with bevacizumab. Complete remission of the rash was achieved after performing 30% salicylic peels, and the patient continued the chemotherapy as planned with no need of either dose reduction or discontinuation of bevacizumab.
Keywords
Hrčak ID:
187822
URI
Publication date:
19.10.2017.
Visits: 911 *